Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment

BMC Dermatology

Volumn 14, Issue 1, 2014, Pages

  Boggs, Robert L ^a   Kárpáti, Sarolta ^b   Li, Wenzhi ^a   Williams, Theresa ^a   Pedersen, Ronald ^a   Mallbris, Lotus ^a   Gniadecki, Robert ^c  

^a PFIZER INC   (United States)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Employment; Etanercept; Pharmacoeconomics; Psoriasis; Psoriatic arthritis; Sick days

Indexed keywords

ETANERCEPT; IMMUNOGLOBULIN G; NONSTEROID ANTIINFLAMMATORY AGENT; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; ASIAN; BODY MASS; BODY SURFACE; CONTROLLED STUDY; DISEASE DURATION; EMPLOYMENT STATUS; EUROPEAN; FEMALE; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; JOB CHANGE; JOB RESPONSIBILITY; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; MULTICENTER STUDY; OPEN STUDY; PSORIASIS; PSORIATIC ARTHRITIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RESPONSIBILITY; SINGLE BLIND PROCEDURE; SOUTH AND CENTRAL AMERICA; WORK; ARTHRITIS, PSORIATIC; COST OF ILLNESS; DOUBLE BLIND PROCEDURE; ECONOMICS; EMPLOYMENT; MIDDLE AGED;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, PSORIATIC; COST OF ILLNESS; DOUBLE-BLIND METHOD; EMPLOYMENT; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; QUESTIONNAIRES; RECEPTORS, TUMOR NECROSIS FACTOR; SICK LEAVE;

EID: 84906832735     PISSN: None     EISSN: 14715945     Source Type: Journal    
DOI: 10.1186/1471-5945-14-14     Document Type: Article

References (16)

1. Gladman DD. Psoriatic arthritis. Dermatol Ther 2004, 17:350-363. 10.1111/j.1396-0296.2004.04038.x, 15379770.
2. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatol Treat 2008, 19:5-21.
3. Mease P. Management of psoriatic arthritis: the therapeutic interface between rheumatology and dermatology. Curr Rheumatol Rep 2006, 8:348-354. 10.1007/s11926-006-0064-9, 16973108.
4. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004, 9:136-139. 10.1046/j.1087-0024.2003.09102.x, 15083780.
5. Dubertret L, Mrowietz U, Ranki A, van de Kerkhof PC, Chimenti S, Lotti T, Scha¨fer G. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006, 155:729-736. 10.1111/j.1365-2133.2006.07405.x, 16965422.
6. Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004, 51:704-708. 10.1016/j.jaad.2004.04.014, 15523347.
7. Zachariae H, Zachariae R, Blomqvist K, Davidsson S, Molin L, Mørk C, Sigurgeirsson B. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol 2002, 82:108-113. 10.1080/00015550252948130, 12125937.
8. Radtke MA, Reich K, Blome C, Rustenbach S, Augustin M. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol 2009, 23:683-691. 10.1111/j.1468-3083.2009.03159.x, 19309433.
9. Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD, Estojak J, Molta CT, Freundlich B. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010, 340:c147. 10.1136/bmj.c147, 20124563.
10. Gniadecki R, Robertson D, Molta CT, Freundlich B, Pedersen R, Li W, Boggs R, Zbrozek AS. Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens. J Eur Acad Dermatol Venereol 2012, 26:1436-1443. 10.1111/j.1468-3083.2011.04308.x, 22035157.
11. Prinz JC, Fitzgerald O, Boggs RI, Foehl J, Robertson D, Pedersen R, Molta CT, Freundlich B. Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial. J Eur Acad Dermatol Venereol 2011, 25:559-564. 10.1111/j.1468-3083.2010.03838.x, 20840349.
12. Short-Term Labour Market Statistics: Employment Rate. http://stats.oecd.org/Index.aspx?QueryId=38900.
13. Gladman DD, Bombardier C, Thorne C, Haraoui B, Khraishi M, Rahman P, Bensen W, Syrotuik J, Poulin-Costello M. Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial. J Rheumatol 2011, 38:1355-1362. 10.3899/jrheum.100698, 21572156.
14. Wallenius M, Skomsvoll JF, Koldingsnes W, Rødevand E, Mikkelsen K, Kaufmann C, Kvien TK. Work disability and health-related quality of life in males and females with psoriatic arthritis. Ann Rheum Dis 2009, 68:685-689. 10.1136/ard.2008.092049, 18511544.
15. Pearce DJ, Singh S, Balkrishnan R, Kulkarni A, Fleischer AB, Feldman SR. The negative impact of psoriasis on the workplace. J Dermatol Treat 2006, 17:24-28.
16. Zhang W, Bansback N, Boonen A, Young A, Singh A, Anis AH. Validity of the work productivity and activity impairment questionnaire-general health version in patients with rheumatoid arthritis. Arthritis Res Ther 2010, 12:R177. 10.1186/ar3141, 2991008, 20860837.